Search clinical trials for: BMS-986315

Total 3180 results

Bristol-Myers Squibb

Completed

Study of Relatlimab in Combination With Nivolumab in Chinese Participants (RELATIVITY-111)

Advanced Solid Tumors

China
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Active, not recruiting

Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors

Cancer

Japan
Bristol-Myers Squibb

Completed

Pharmacokinetics and Metabolism Study in Healthy Male Participants

Cancer

United States
Dragonfly Therapeutics

Recruiting

A Study of DF6002 Alone and in Combination With Nivolumab

Solid Tumors

United States, Spain, Australia, France
PDL BioPharma, Inc.

Terminated

An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis

Ulcerative Colitis

Belgium, France, United States, Italy, Australia, Czech Republic, Netherlands, Ireland, Norway, Canada, Austria, Germany, Hungary, Ukraine
Bristol-Myers Squibb

Active, not recruiting

A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

United States, France, Australia, Canada, Italy, Norway, Spain, Sweden, United Kingdom
PrECOG, LLC.
Bristol-Myers Squibb

Completed

Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer (PrE0807)

Bladder Cancer

United States
Bristol-Myers Squibb

Recruiting

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Norway, United States, Spain, United Kingdom, Canada
Bristol-Myers Squibb

Completed

A Study to Evaluate the Bioavailability of BMS-986205

Healthy Participants

United Kingdom
Bristol-Myers Squibb

Completed

An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers

Gastric Cancer | Esophagogastric Junction | Cancer of the Stomach

United States, Germany, Italy, Argentina, Australia, Belgium, France, Poland, Puerto Rico, Spain, Czechia, Austria, Canada, United Kingdom, Chile, Norway, Singapore
Nektar Therapeutics
Bristol-Myers Squibb

Completed

A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer (PIVOT-10)

Neoplasm Metastasis | Urinary Bladder Neoplasm

United States, Spain, United Kingdom, Belgium, Canada, Australia, France, Italy, Greece, Germany, Portugal, Argentina, Israel, Russian Federation, Turkey, Mexico, Finland, Netherlands
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma (RELATIVITY-069)

Lymphoma, Non-Hodgkin | Hodgkin Disease

United States, France, Netherlands, Australia, United Kingdom, Italy, Spain, Germany
Bristol-Myers Squibb
Nektar Therapeutics

Completed

A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma

Melanoma

Canada, Australia, France, Italy, Brazil, United States, Argentina, Austria, Belgium, Chile, Czechia, Finland, Germany, Greece, Ireland, Israel, Mexico, Netherlands, New Zealand, Poland, Portugal, Romania, Russian Federation, Spain, Sweden and more
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd; Nektar Therapeutics

Completed

An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid Tumors

Advanced Cancer

Japan
M.D. Anderson Cancer Center

Recruiting

Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla

Renal Medullary Carcinoma | Carcinomas

United States
Bristol-Myers Squibb
Eisai Inc.

Recruiting

A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC)

Carcinoma, Non-Small-Cell Lung

United States, Australia, Belgium, Chile, France, Spain
Nektar Therapeutics
Bristol-Myers Squibb

Terminated

Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12)

Melanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III

United States, Spain, Germany, France, Australia, Italy, Greece, Israel, Russian Federation, New Zealand, Austria, United Kingdom, Netherlands, Portugal, Poland, Czechia, Romania
H. Lee Moffitt Cancer Center and Research Institute
Secura Bio, Inc.

Active, not recruiting

Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy

Hodgkin Lymphoma | Non Hodgkin Lymphoma | Myeloma | Lymphocytic Leukemia

United States
Bristol-Myers Squibb

Completed

A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced Tumors

Advanced Cancer

Japan
Bristol-Myers Squibb

Completed

An Investigational Study to Evaluate Experimental Medication BMS-986165 in Japanese Participants With Moderate-to-Severe Psoriasis

Psoriasis

Japan
Bristol-Myers Squibb

Completed

A Study to Assess the Safety of Experimental Medication BMS986165 in Participants With Normal Kidney Function and Participants With Mild to End-Stage Kidney Disease.

Renal Impairment | Healthy Volunteer

United States, Czechia, Hungary, Poland
Bristol-Myers Squibb

Completed

Assessment of Gut Absorption of Experimental Medication BMS-986165 in Healthy Males

Psoriasis

United States
Bristol-Myers Squibb

Completed

Safety, Tolerability and Relative Bioavailability Study of BMS-986195 in Healthy Subjects

Rheumatoid Arthritis

Australia
Celgene

Not yet recruiting

Study to Evaluate Safety, Drug Levels, Food and Relative Bioavailability of BMS-986365 in Healthy Adult Male Participants

Healthy Participants

United States
Bristol-Myers Squibb

Active, not recruiting

Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

Korea, Republic of, Canada, Japan, United States, Taiwan, Mexico, Argentina, Brazil, Colombia, Hungary, Poland, Romania, Russian Federation, Spain
Bristol-Myers Squibb
Nektar Therapeutics

Completed

A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer

Bladder Cancer | Bladder Tumor | Muscle-Invasive Bladder Cancer

Russian Federation, China, Germany, Italy, United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Czechia, France, Greece, Israel, Mexico, Netherlands, Poland, Spain, United Kingdom
Bristol-Myers Squibb

Recruiting

A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations

Melanoma

Spain, United States, Italy, Chile, Greece, Argentina
Bristol-Myers Squibb

Withdrawn

An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | Lung Cancer

Italy, Korea, Republic of, Turkey, Canada, Spain, Australia, Mexico, Taiwan, France, Germany, Switzerland, Greece, Japan, Austria, United States, Brazil, Czechia
Bristol-Myers Squibb

Completed

An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread

Melanoma | Non-Small Cell Lung Cancer | Advanced Cancer

Canada, United States, Australia, France, Italy, Spain, Finland, Germany, Norway, Poland, Sweden
Bristol-Myers Squibb

Active, not recruiting

Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (POETYK PSO-LTE)

Psoriasis

China, Taiwan, Spain, United States, Hungary, Canada, Germany, Japan, Australia, Poland, Czechia, United Kingdom, Korea, Republic of, Israel, New Zealand, Sweden, France, Finland, Russian Federation, Puerto Rico
Bristol-Myers Squibb

Completed

A Study to Assess Relative Bioavailability of Branebrutinib, From a Tablet Formulation to the Capsule Formulation, the Effect of Food on the Bioavailability of Branebrutinib From a Tablet Formulation, and the Safety and Drug Levels of Branebrutinib From a Tablet Formulation in Healthy Participants

Healthy Volunteers

United States
Bristol-Myers Squibb

Completed

Single and Multiple Dose Pharmacokinetics of BMS-986165 in a Randomized, Double-Blind, Placebo-Controlled Study in Healthy Chinese Subjects

Autoimmune Diseases

China
Bristol-Myers Squibb

Completed

A Study of BMS-986195 in Healthy Male Subjects

Rheumatoid Arthritis

Netherlands
Bristol-Myers Squibb

Completed

A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors

Advanced Cancer

China
Bristol-Myers Squibb

Recruiting

ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions (ELEMENT-MDS)

Myelodysplastic Syndromes

Canada, United States, China, Australia, France, Greece, Hungary, Germany, Italy, Czechia, Poland, Mexico, Spain, Brazil, Colombia, India, Argentina, Puerto Rico
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome (POETYK SjS-1)

Sjögren's Syndrome

United States, Australia, Germany, Korea, Republic of, China, Austria, Spain, Japan, Taiwan, Puerto Rico, Poland, Canada, Hungary, Chile, Denmark, France, Italy, Mexico, Peru, Netherlands, Belgium, Colombia, United Kingdom, Portugal, Sw... and more
Bristol-Myers Squibb

Terminated

A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata

Alopecia Areata

Canada, France, Japan, Australia, United States, Poland
Bristol-Myers Squibb

Completed

Safety and Efficacy of Deucravacitinib in Participants With Moderate to Severe Ulcerative Colitis

Ulcerative Colitis

Korea, Republic of, United States, Australia, Hungary, Germany, Italy, United Kingdom, Czechia, Japan, Russian Federation, France, Belgium, Poland
Bristol-Myers Squibb

Completed

An Investigational Study to Evaluate Experimental Medication BMS-986165 Given as a Tablet and Solution in Healthy Male Participants

Healthy Participants

United Kingdom
Bristol-Myers Squibb

Active, not recruiting

A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors

Hepatocellular Carcinoma | Hepatoma | Liver Cell Carcinoma | Liver Cancer, Adult | Liver Cell Carcinoma, Adult

Chile, Brazil, Argentina, China, Czechia, France, Hong Kong, Japan, Korea, Republic of, Mexico, New Zealand, Poland, Romania, Singapore, Spain, Taiwan, Turkey
Bristol-Myers Squibb

Active, not recruiting

A Study to Evaluate the Efficacy, Safety, and Tolerability of MYK-224 in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy (MERCUTIO)

Cardiomyopathy, Hypertrophic

Italy, United States, Poland, Spain
Bristol-Myers Squibb

Completed

An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo in Participants With Plaque Psoriasis (POETYK-PSO-3) in Mainland China, Taiwan, and South Korea (POETYK-PSO-3)

Psoriasis

China, Korea, Republic of, Taiwan
Bristol-Myers Squibb

Completed

A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors

CANCER,NOS

France, Canada, United States, Switzerland, Spain, Italy
Celgene

Active, not recruiting

A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders

Neoplasms | Hematologic Malignancies | Hematologic Neoplasm

United Kingdom, United States
Bristol-Myers Squibb

Recruiting

A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission

Acute Myeloid Leukemia

Japan, United States
Bristol-Myers Squibb

Recruiting

A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors

Melanoma | Carcinoma, Renal Cell | Cervical Cancer | Pancreatic Adenocarcinoma | Ovarian Neoplasms | Squamous Cell Carcinoma of Head and Neck | Triple Negative Breast Neoplasms | Urothelial Carcinoma | Microsatellite Stable Colorectal Cancer | Non-Small-Cell Lung Cancer | Gastric/Gastroesophageal Junction...

United States, Australia, Italy, Germany, Spain, Canada, Israel, Japan
Bristol-Myers Squibb

Recruiting

A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis

Palmoplantar Psoriasis | Genital Psoriasis

United States, Germany, Spain, Italy, Poland, Argentina, Canada
Bristol-Myers Squibb

Active, not recruiting

Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp Psoriasis

Psoriasis

United States, France, Germany, Poland, United Kingdom
Mayo Clinic
Bristol-Myers Squibb

Recruiting

A Study of Deucravacitinib to Treat LPP and FFA

Lichen Planopilaris

United States
Bristol-Myers Squibb

Completed

An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread.

Solid Tumors

United States, Australia, Spain, Germany, France, Switzerland, Netherlands, Canada, Belgium, Italy

Search clinical trials for: BMS-986315

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Nigeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations